Northland Securities Predicts Nephros Q4 Earnings

Nephros Inc. (NASDAQ:NEPH) – Equities research analysts at Northland Securities issued their Q4 2026 earnings per share (EPS) estimates for shares of Nephros in a research note issued on Thursday, August 13th. Northland Securities analyst B. Brooks anticipates that the company will post earnings per share of $0.01 for the quarter. Northland Securities currently has a “Market Perform” rating and a $4.00 price objective on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.03 per share.

Nephros (NASDAQ:NEPH) last released its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter. The company had revenue of $6.02 million during the quarter, compared to analysts’ expectations of $4.99 million. Nephros had a net margin of 8.38% and a return on equity of 11.03%.

Other research analysts have also recently issued research reports about the company. Zacks Research upgraded Nephros to a “hold” rating in a research report on Monday, July 20th. Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.00.

Nephros Price Performance

NEPH opened at $4.69 on Friday. Nephros has a 12 month low of $2.66 and a 12 month high of $6.42. The stock has a market capitalization of $50.93 million, a P/E ratio of 29.31 and a beta of 1.51. The business has a 50 day simple moving average of $3.54 and a 200-day simple moving average of $3.51.

Institutional Investors Weigh In On Nephros

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Nephros by 3.2% during the second quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after buying an additional 2,898 shares in the last quarter. Topline Capital Management LLC raised its holdings in shares of Nephros by 13.1% in the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after acquiring an additional 55,360 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Nephros in the third quarter valued at $64,000. Citadel Advisors LLC lifted its position in shares of Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after acquiring an additional 4,655 shares in the last quarter. Finally, Navellier & Associates Inc. purchased a new stake in shares of Nephros in the fourth quarter valued at $133,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.